UCLA Heart Failure Symposium 2025: State-of-the-Art Updates & Therapies for Advanced Heart Failure


UCLA Heart Failure Symposium 2025: State-of-the-Art Updates & Therapies for Advanced Heart Failure Banner

Add to Calendar UCLA Heart Failure Symposium 2025: State-of-the-Art Updates & Therapies for Advanced Heart Failure 9/20/2025 7:00:00 AM 9/20/2025 5:00:00 PM America/Los_Angeles For More Details: https://ucla.cloud-cme.com/HF2025 Description: Heart failure affects approximately six million Americans and is the most common diagnosis for acute hospitalization in patients over 65 years. Over the next decade, we will see a dramatic increase in the number of patients in the community with advanced heart failure who can benefit from advanced therapies for complex cardiac disease. Academic medical centers, such as UCLA, have an opportunity to integrate treatment advances i... Marina del Rey Marriott false MM/DD/YYYY


Date & Location
Saturday, September 20, 2025, 7:00 AM - 5:00 PM, Marina del Rey Marriott, Marina del Rey, CA

Overview

Heart failure affects approximately six million Americans and is the most common diagnosis for acute hospitalization in patients over 65 years. Over the next decade, we will see a dramatic increase in the number of patients in the community with advanced heart failure who can benefit from advanced therapies for complex cardiac disease. Academic medical centers, such as UCLA, have an opportunity to integrate treatment advances into a comprehensive patient-centered heart failure management program. UCLA Health wants to enhance the role of the primary care physician and primary cardiologist as the central provider for continuity of care for these complex heart failure patients.

The 13th Annual UCLA Heart Failure Symposium 2025 will:

1. Discuss general heart failure treatment options including short and long term mechanical circulatory support therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous and structural interventions, and complex congenital heart disease management.

2. Emphasize the need for developing networks linking academic centers with community physicians to manage these patients through the evolution of their disease pre and post advanced cardiac intervention.

3. Discuss heart failure therapies in cardio-oncology, amyloidosis and new medication updates, as well as address patient and care-provider’s specific needs and perspectives.


Registration

In-Person & Virtual Registration Fees

In-person registration includes access to the course materials, breakfast, patio lunch and reception at the meeting site. Virtual registration includes access to the live stream virtual conference.

  • $100 Live Virtual Conference

  • $125 Live In-Person Conference

Recharge Payment Information
Registration payment can be submitted via the Interdepartmental recharge system.
For more details, please refer to document here: Recharge Information

Refunds
Due to the low enrollment fee, no refunds will be offered. A full refund will be provided if this course is cancelled, or postponed. David Geffen School of Medicine at UCLA reserves the right to cancel or postpone this course if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs, such as non-refundable airline tickets or hotel penalties.

Course Recording
All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.

The recorded sessions are not approved for Continuing Education (CE) credit.

Questions
If you have questions about enrollment, please email [email protected] or call (310) 794-2620.


Target Audience
Specialties - Family Medicine, Internal Medicine, Pediatrics
Professions - Fellow/Resident, Nurse, Physician

Objectives
At the conclusion of this activity, learners will be able to:

  1. Identify the epidemiology and pathophysiology of heart failure and the need for mechanical circulatory support with a growing heart failure population.
  2. Identify indications for and management of lifelong left ventricular assist device therapy.
  3. Implement shared care programs with the community and co-manage patients in need of complex cardiac therapies including LVAD therapy, heart transplantation, pulmonary hypertension management, high risk percutaneous interventions, and complex congenital heart disease management.
  4. Discuss the comprehensive multidisciplinary care and services available to complex cardiac patients within the UCLA Heart Failure Program.

Accreditation

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the AMA PRA Category 1 Credits™. as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies. 


Credits
AMA PRA Category 1 Credits™ (6.25 hours), Non-Physician Attendance (6.25 hours)

Keywords: